Literature DB >> 8965245

Evaluation of mitomycin to limit postoperative adhesions in strabismus surgery.

O A Cruz1.   

Abstract

BACKGROUND: Ocular motility dysfunction following strabismus surgery may be the result of postoperative scarring or the formation of adhesions. Mitomycin C (MMC) has been used with encouraging results as an adjunct to standard treatment of hypertrophic conjunctival scars after strabismus surgery. It has been demonstrated that MMC does not inhibit muscle reattachment and might inhibit adhesions and scar formation in the rabbit. We investigated in a rabbit model effectiveness of MMC in reducing the formation of postoperative adhesions following reoperations and the tensile strength of the new musculo-scleral junction.
METHODS: A prospective, masked-observer, controlled study was performed in rabbits. Symmetrical bilateral recessions of the superior and inferior rectus muscles were performed on each rabbit. A reoperation was performed 6 weeks later, in which the muscles were advanced back to their original insertion. During the reoperation, one eye served as the control while the other was treated with a 5-minute intraoperative exposure to topical mitomycin.
RESULTS: Mitomycin reduced the formation of adhesions and the amount of postoperative scarring. The tensile strength of the musculo-scleral junction was reduced in the mitomycin-treated eyes but exceeded the force generated during extraocular ductions.
CONCLUSION: MMC may be an effective adjunctive therapy in the treatment of strabismus associated with pre-existing adhesions or scarring.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8965245     DOI: 10.3928/0191-3913-19960301-06

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  9 in total

1.  Study of Endonasal Endoscopic Dacryo-cystorhinostomy with Special Reference to Mitomycin-C.

Authors:  Madhu Priya; Manish P Puttewar; Shraddha Jain Kumar; Satvinder Singh Bakshi
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-05-10

2.  Amniotic membrane in the management of strabismus reoperations.

Authors:  Betul Tugcu; Firat Helvacioglu; Erdal Yuzbasioglu; Ceren Gurez; Ulviye Yigit
Journal:  Jpn J Ophthalmol       Date:  2012-12-13       Impact factor: 2.447

3.  Effect of ADCON-L on adjustable strabismus surgery in rabbits.

Authors:  M Y Choi; S J Auh; D G Choi; B L Chang
Journal:  Br J Ophthalmol       Date:  2001-01       Impact factor: 4.638

4.  Topical application of mitomycin C prevents epineural scar formation in rats.

Authors:  Konuralp Ilbay; Volkan Etus; Kursat Yildiz; Gul Ilbay; Savas Ceylan
Journal:  Neurosurg Rev       Date:  2004-12-03       Impact factor: 3.042

5.  Prevention of Intraabdominal Adhesions: An Experimental Study Using Mitomycin-C and 4% Icodextrin.

Authors:  Murat Urkan; İsmail Hakkı Özerhan; Aytekin Ünlü; Mehmet Fatih Can; Erkan Öztürk; Armağan Günal; Gökhan Yağcı
Journal:  Balkan Med J       Date:  2017-01-05       Impact factor: 2.021

6.  Dried human amniotic membrane does not alleviate inflammation and fibrosis in experimental strabismus surgery.

Authors:  Bo Young Chun; Hong Kyun Kim; Jae Pil Shin
Journal:  J Ophthalmol       Date:  2013-06-23       Impact factor: 1.909

7.  Potential risk of mitomycin C at high concentrations on peripheral nerve structure.

Authors:  Tao Sui; Jinhong Zhang; Shihao Du; Changhui Su; Jun Que; Xiaojian Cao
Journal:  Neural Regen Res       Date:  2014-04-15       Impact factor: 5.135

8.  Effective treatment for prevention of post-operative adhesion after strabismus surgery in experimental rabbit model: 0.5 % tranilast ophthalmic solution.

Authors:  Sang Uk Choi; Kyoung Woo Kim; Nam Ju Moon
Journal:  BMC Ophthalmol       Date:  2016-09-21       Impact factor: 2.209

9.  Cryopreserved rabbit amniotic membrane alleviated inflammatory response and fibrosis following experimental strabismus surgery in rabbits.

Authors:  Bo Young Chun; Soolienah Rhiu
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.